within Pharmacolibrary.Drugs.ATC.J;

model J05AB03
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0009,
    adminDuration  = 600,
    adminMass      = 750 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0007,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0004,
    k12             = 36,
    k21             = 36
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J05AB03</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Vidarabine (adenine arabinoside, Ara-A) is a purine nucleoside analogue antiviral that was historically used to treat herpes simplex virus (HSV) and varicella-zoster virus (VZV) infections, including herpes encephalitis and herpes keratitis. Its use has declined due to the availability of safer and more effective antivirals like acyclovir; vidarabine is no longer commonly used or approved in current clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in adult patients after intravenous administration, primarily for herpes simplex treatment. Published data refer to adult populations without significant organ impairment.</p><h4>References</h4><ol><li><p>Ghobadi, A, et al., &amp; Strati, P (2025). Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial. <i>Lancet (London, England)</i> 405(10473) 127–136. DOI:<a href=\"https://doi.org/10.1016/S0140-6736(24)02462-0\">10.1016/S0140-6736(24)02462-0</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39798981/\">https://pubmed.ncbi.nlm.nih.gov/39798981</a></p></li><li><p>Kikuchi, T, et al., &amp; Okamoto, S (2021). Pharmacokinetics of intravenous busulfan as condition for hematopoietic stem cell transplantation: comparison between combinations with cyclophosphamide and fludarabine. <i>International journal of hematology</i> 113(1) 128–133. DOI:<a href=\"https://doi.org/10.1007/s12185-020-02990-y\">10.1007/s12185-020-02990-y</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32886279/\">https://pubmed.ncbi.nlm.nih.gov/32886279</a></p></li><li><p>Kuo, GM, et al., &amp; Burstein, AH (2001). Fludarabine pharmacokinetics after subcutaneous and intravenous administration in patients with lupus nephritis. <i>Pharmacotherapy</i> 21(5) 528–533. DOI:<a href=\"https://doi.org/10.1592/phco.21.6.528.34549\">10.1592/phco.21.6.528.34549</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11349741/\">https://pubmed.ncbi.nlm.nih.gov/11349741</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J05AB03;
